Achillion Readies A Nuc Combo As Acquisition Speculation Swirls
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.